ASX - By Stock
|
WA1 |
Re:
General discussion
|
|
maslow
|
13K |
3.5M |
3 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
13K
|
3.5M
|
3
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Understanding Telix
|
|
maslow
|
1.5K |
770K |
1 |
07/12/23 |
07/12/23 |
ASX - By Stock
|
1.5K
|
770K
|
1
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Understanding Telix
|
|
maslow
|
1.5K |
770K |
0 |
07/12/23 |
07/12/23 |
ASX - By Stock
|
1.5K
|
770K
|
0
|
|
ASX - By Stock
|
PTX |
Re:
oppies
|
|
maslow
|
314 |
96K |
5 |
05/04/23 |
05/04/23 |
ASX - By Stock
|
314
|
96K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Response to ASX Price Query
|
|
maslow
|
40 |
10K |
2 |
13/09/22 |
13/09/22 |
ASX - By Stock
|
40
|
10K
|
2
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Change of Director's Interest Notices x2
|
|
maslow
|
204 |
67K |
2 |
12/01/22 |
12/01/22 |
ASX - By Stock
|
204
|
67K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Investor Video Noxopharm 2021 AGM
|
|
maslow
|
6 |
2.0K |
6 |
28/11/21 |
28/11/21 |
ASX - By Stock
|
6
|
2.0K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Licencing Deal Expands Noxopharm Drug Opportunities
|
|
maslow
|
12 |
3.3K |
3 |
17/11/21 |
17/11/21 |
ASX - By Stock
|
12
|
3.3K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Trading Halt
|
|
maslow
|
47 |
14K |
2 |
15/11/21 |
15/11/21 |
ASX - By Stock
|
47
|
14K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Trading Halt
|
|
maslow
|
47 |
14K |
4 |
15/11/21 |
15/11/21 |
ASX - By Stock
|
47
|
14K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Ann: September 2021 Quarterly Activities Report and Appendix 4C
|
|
maslow
|
16 |
4.1K |
12 |
14/10/21 |
14/10/21 |
ASX - By Stock
|
16
|
4.1K
|
12
|
|
ASX - By Stock
|
PAB |
Re:
Ann: PAT-DX3 proof of concept as potential ADC targeting antibody
|
|
maslow
|
134 |
37K |
3 |
22/09/21 |
22/09/21 |
ASX - By Stock
|
134
|
37K
|
3
|
|
ASX - By Stock
|
PAB |
Re:
Ann: PAT-DX3 proof of concept as potential ADC targeting antibody
|
|
maslow
|
134 |
37K |
3 |
21/09/21 |
21/09/21 |
ASX - By Stock
|
134
|
37K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Trading Halt
|
|
maslow
|
71 |
23K |
6 |
19/08/21 |
19/08/21 |
ASX - By Stock
|
71
|
23K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Trading Halt
|
|
maslow
|
71 |
23K |
14 |
19/08/21 |
19/08/21 |
ASX - By Stock
|
71
|
23K
|
14
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm Secures Key European Patent Allowance for Veyonda
|
|
maslow
|
40 |
14K |
6 |
29/06/21 |
29/06/21 |
ASX - By Stock
|
40
|
14K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm Secures Key European Patent Allowance for Veyonda
|
|
maslow
|
40 |
14K |
3 |
29/06/21 |
29/06/21 |
ASX - By Stock
|
40
|
14K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Chart
|
|
maslow
|
15 |
6.0K |
7 |
09/02/21 |
09/02/21 |
ASX - By Stock
|
15
|
6.0K
|
7
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda To Be Tested In Combination With Opdivo In Trial
|
|
maslow
|
8 |
2.4K |
5 |
09/11/20 |
09/11/20 |
ASX - By Stock
|
8
|
2.4K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
Ann: NOXCOVID Study Cleared To Expand
|
|
maslow
|
1 |
746 |
4 |
05/11/20 |
05/11/20 |
ASX - By Stock
|
1
|
746
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda COVID-19 Study Approved For Immediate Start
|
|
maslow
|
6 |
2.6K |
5 |
01/09/20 |
01/09/20 |
ASX - By Stock
|
6
|
2.6K
|
5
|
|
ASX - By Stock
|
PTX |
Re:
Fair Valuation of PTX
|
|
maslow
|
266 |
85K |
3 |
18/08/20 |
18/08/20 |
ASX - By Stock
|
266
|
85K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
MESO action tonight
|
|
maslow
|
3.1K |
1.4M |
6 |
11/08/20 |
11/08/20 |
ASX - By Stock
|
3.1K
|
1.4M
|
6
|
|
ASX - By Stock
|
PTX |
Re:
Ann: 2 PTX Assets Chosen in Doherty Institute COVID-19 Program
|
|
maslow
|
107 |
35K |
7 |
21/07/20 |
21/07/20 |
ASX - By Stock
|
107
|
35K
|
7
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Data Shows Idronoxil Holds Key to Problem of COLD Cancers
|
|
maslow
|
14 |
6.5K |
5 |
20/07/20 |
20/07/20 |
ASX - By Stock
|
14
|
6.5K
|
5
|
|
ASX - By Stock
|
PTX |
Re:
car t therapy govt funding
|
|
maslow
|
23 |
8.6K |
8 |
29/05/20 |
29/05/20 |
ASX - By Stock
|
23
|
8.6K
|
8
|
|
ASX - By Stock
|
PTX |
Re:
Ann: Trading Halt
|
|
maslow
|
229 |
70K |
3 |
25/05/20 |
25/05/20 |
ASX - By Stock
|
229
|
70K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
COVID-19 ARDS and ARDS Share Price Scenarios
|
|
maslow
|
518 |
268K |
2 |
24/05/20 |
24/05/20 |
ASX - By Stock
|
518
|
268K
|
2
|
|
ASX - By Stock
|
PTX |
Re:
Ann: Trading Halt
|
|
maslow
|
229 |
70K |
1 |
24/05/20 |
24/05/20 |
ASX - By Stock
|
229
|
70K
|
1
|
|
ASX - By Stock
|
PTX |
Re:
Ann: Trading Halt
|
|
maslow
|
229 |
70K |
5 |
24/05/20 |
24/05/20 |
ASX - By Stock
|
229
|
70K
|
5
|
|
ASX - By Stock
|
PTX |
Re:
Ann: Trading Halt
|
|
maslow
|
229 |
70K |
9 |
21/05/20 |
21/05/20 |
ASX - By Stock
|
229
|
70K
|
9
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
maslow
|
23K |
13M |
4 |
06/05/20 |
06/05/20 |
ASX - By Stock
|
23K
|
13M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L
|
|
maslow
|
847 |
340K |
10 |
25/04/20 |
25/04/20 |
ASX - By Stock
|
847
|
340K
|
10
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm Investigating Potential COVID-19 Treatment
|
|
maslow
|
34 |
18K |
6 |
02/04/20 |
02/04/20 |
ASX - By Stock
|
34
|
18K
|
6
|
|
ASX - By Stock
|
BNO |
Re:
Ann: Commencement of BNC210 Phase 2 Agitation Trial
|
|
maslow
|
34 |
16K |
2 |
23/05/18 |
23/05/18 |
ASX - By Stock
|
34
|
16K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: MSB Clinical Program Update For MPC-150-IM In Heart Failure
|
|
maslow
|
116 |
45K |
10 |
18/04/18 |
18/04/18 |
ASX - By Stock
|
116
|
45K
|
10
|
|
ASX - By Stock
|
PAB |
Re:
Ann: PAT-DX1 Targets Nanoparticles to Breast Cancer
|
|
maslow
|
34 |
16K |
5 |
29/01/18 |
29/01/18 |
ASX - By Stock
|
34
|
16K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
interesting... conflict of interest?
|
|
maslow
|
74 |
19K |
1 |
21/12/17 |
21/12/17 |
ASX - By Stock
|
74
|
19K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
interesting... conflict of interest?
|
|
maslow
|
74 |
19K |
5 |
21/12/17 |
21/12/17 |
ASX - By Stock
|
74
|
19K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
interesting... conflict of interest?
|
|
maslow
|
74 |
19K |
5 |
21/12/17 |
21/12/17 |
ASX - By Stock
|
74
|
19K
|
5
|
|
ASX - By Stock
|
BNO |
Re:
Ann: Becoming a substantial holder
|
|
maslow
|
3 |
3.3K |
4 |
08/06/17 |
08/06/17 |
ASX - By Stock
|
3
|
3.3K
|
4
|
|
ASX - By Stock
|
IPD |
Re:
Ann: L-Dex Study - Significant Reduction in Clinical Lymphoedema
|
|
maslow
|
108 |
50K |
0 |
31/05/17 |
31/05/17 |
ASX - By Stock
|
108
|
50K
|
0
|
|
ASX - By Stock
|
IPD |
Re:
Ann: L-Dex Study - Significant Reduction in Clinical Lymphoedema
|
|
maslow
|
108 |
50K |
2 |
31/05/17 |
31/05/17 |
ASX - By Stock
|
108
|
50K
|
2
|
|
ASX - By Stock
|
BNO |
Re:
Volume
|
|
maslow
|
9 |
4.5K |
0 |
22/05/17 |
22/05/17 |
ASX - By Stock
|
9
|
4.5K
|
0
|
|
ASX - By Stock
|
BNO |
Re:
Volume
|
|
maslow
|
9 |
4.5K |
0 |
16/05/17 |
16/05/17 |
ASX - By Stock
|
9
|
4.5K
|
0
|
|
ASX - By Stock
|
ATX |
Re:
Ann: American Academy of Neurologists Posters & KOL Presentation
|
|
maslow
|
15 |
5.7K |
6 |
01/05/17 |
01/05/17 |
ASX - By Stock
|
15
|
5.7K
|
6
|
|
ASX - By Stock
|
ATX |
Re:
Conference Started Sunday April 23
|
|
maslow
|
22 |
7.3K |
5 |
27/04/17 |
27/04/17 |
ASX - By Stock
|
22
|
7.3K
|
5
|
|
ASX - By Stock
|
QIN |
Re:
Santalis Pharmaceuticals - patent granted
|
|
maslow
|
13 |
5.0K |
1 |
24/04/17 |
24/04/17 |
ASX - By Stock
|
13
|
5.0K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
AFR - 10 Aril 2017
|
|
maslow
|
47 |
21K |
5 |
10/04/17 |
10/04/17 |
ASX - By Stock
|
47
|
21K
|
5
|
|
ASX - By Stock
|
ATX |
Newsletter worth reading about mechanism of action and previous results re-analysed
|
|
maslow
|
1 |
1.1K |
3 |
10/04/17 |
10/04/17 |
ASX - By Stock
|
1
|
1.1K
|
3
|
|